TOKISAKE-ASSOCIATION
20.11.2020 11:32:10 CET | Business Wire | Press release
The Tokisake Association (located in Kyoto Prefecture, President, Tokubee Masuda) was established in August 2019 with the aim of reviving the culture of aged sake and establishing and further enhancing the value of sake to the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005313/en/
The company will sell the highest-priced product in the history of Japanese sake, “Toki no Shirabe” in a limited edition of 20 sets of 8 bottles (720 ml) for 2,020,000 yen, for domestic and international customers to commemorate the establishment of the Association.
In addition to seven bottles of secret sake commercialized from each of the seven breweries that are the founding members of the Association, another very rare bottle is an assemblage (blend) by the world-renowned sommelier Mr. Shinya Tasaki, to complete a limited edition of eight bottles.
By releasing this ultra-gorgeous new product, which is a collection of excellent products engraved over the years, they will continue to contribute to the creation of even more value for Japanese sake in Japan and abroad.
[New Product Overview]
Product Name: [Special Limited] Aged sake set of 8 bottles of "Toki no Shirabe"
Price: 2.02 million yen
Booking period: November 24 (Tuesday) to December 5 (Saturday)
Pre-orders are accepted at: Shusaron.com (https://shusaron-online.com/shopdetail/000000000042/
).
If the number of reservation requests exceeds 20, eligible purchasers will be selected by lottery. The set’s gift box is an original work of art by Yoshizawa Ryoichi, an artisan, and is “made of rice husks that are removed during the brewing process and finished with lacquer based on the shape of a traditional Japanese stacked box,” according to Yoshizawa.
[Limited release 8 bottles of sake]
- Masuda Tokubee Shoten Co., Ltd. / Kyoto: “Tsukino Katsura” 1999
- Kokuryu Sake Brewing Corporation / Fukui: Kokuryu "Muni" Junmai Daiginjo Genshu 1996
- DEWAZAKURA SAKE BREWERY CO.,LTD / Yamagata: "Dewazakura Daiginjo Daikoshu cold aged” 1990 & 1986
- Nanbu Bijin Co., Ltd. / Iwate: "Nanbu Bijin All Koji" Junmai 1998
- Shimazaki Shuzo Co., Ltd. / Tochigi: "Azumarikishi Uroko" Daiginjo Genshu 1987
- NAGAI SAKE INC. / Gunma: “Mizubasho Shizuku Daiginjo ice aged" 2003
- Kidoizumi Shuzo Co., Ltd. / Chiba: "Kidoizumi Afs" Yamahai Junmai 1984
- Mr. Shinya Tasaki's assemblage blend, "Toki no Shirabe”
https://www.youtube.com/watch?v=B18SYRjMA8c
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom